{"entity":{"id":"nct05667506","kind":"trial","name":"A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)","aka":[],"tldr":"A phase 1/2 trial of single dose of CNCT19 in acute lymphoblastic leukaemia, run by Juventas Cell Therapy Ltd., now recruiting.","summary":"A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) is a phase 1/2 interventional study registered as NCT05667506 by Juventas Cell Therapy Ltd., with 47 participants planned, started 2023-02-07 and due to reach its primary completion in 2025-05-30. Interventions recorded: single dose of CNCT19.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05667506","url":"https://clinicaltrials.gov/study/NCT05667506"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05667506","phase":"1/2","setting":"A Phase Ib/II, Single Arm, Multi-center Study Evaluating the Safety and Efficacy of CNCT19 in Children and Adolescent(Pediatric) Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)","sponsor":"Juventas Cell Therapy Ltd.","enrolled":47,"outcomes":[]},"route":"/trials/nct05667506/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}]}}